People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other, Biotechnology, Pharmaceuticals, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fluent, Inc. | — | Other | Series D+ | $264.9M | $97.2M | 2015 |
| ChromaDex Corp. | — | Biotechnology | Series B | $110.4M | $46.9M | 2020 |
| BioCardia, Inc. | — | Biotechnology | Series B | $46.1M | $158.8M | 2009 |
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2016 |
| Cocrystal Pharma, Inc. | — | Pharmaceuticals | Series A | $28.9M | $92.9M | 2014 |
| Neovasc Inc | — | Other Health Care | Seed | $1.5M | $37.3M | 2009 |
| OnSource, LLC | — | Other Technology | Seed | $1.5M | $51.1M | 2015 |
Steven Rubin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven Rubin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven D. Rubin | 2 | 9 |
| MICHAEL BRAUSER | 2 | 6 |
| Jeff Baxter | 2 | 4 |
| Jane Hsiao | 2 | 3 |
| Robert Fried | 2 | 2 |
| ROBERT N FRIED | 2 | 2 |
| Steven Gillis | 1 | 23 |
| David Anderson | 1 | 21 |
| Steve Gillis | 1 | 13 |
| Chris Clark | 1 | 9 |
| James Martin | 1 | 9 |
| Mark Friedman | 1 | 8 |
| Barry Honig | 1 | 6 |
| Sam Lee | 1 | 5 |
| Scott Requadt | 1 | 5 |
| JANE H HSIAO | 1 | 5 |
| James Reilly | 1 | 4 |
| Gary Wilcox | 1 | 4 |
| William O'Neill | 1 | 4 |
| Raymond F. Schinazi | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.